Myriad Genetics Inc (NASDAQ:MYGN)
| 12.18 Delayed Data As of Aug 07 |  -0.21 / -1.69%Today’s Change | 9.24 Today|||52-Week Range 47.10 | -55.27% Year-to-Date |
Latest MYGN News | Press Releases
| Myriad Genetics's new technology improves performance of its Prequel NIPS Jul 29 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 12.39 |
| Today’s open | 12.32 |
| Day’s range | 12.11 - 12.54 |
| Volume | 23,430 |
| Average volume (3 months) | 1,075,165 |
| Market cap | $899.9M |
Data as of 3:59pm ET, 08/07/2020
Growth & Valuation
| Earnings growth (last year) | -96.69% |
| Earnings growth (this year) | -111.38% |
| Earnings growth (next 5 years) | -27.41% |
| Revenue growth (last year) | +10.16% |
| P/E ratio | NM |
| Price/Sales | 2.48 |
| Price/Book | 0.81 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AXDXAccelerate Diagnosti... | +0.82 | +5.54% |
| LNTHLantheus Holdings In... | +0.27 | +2.07% |
| VIVOMeridian Bioscience ... | -5.00 | -20.58% |
| TRILTrillium Therapeutic... | +0.86 | +11.64% |
Data as of 5:15pm ET, 08/07/2020
Financials
| Next reporting date | August 13, 2020 |
| EPS forecast (this quarter) | -$0.47 |
| Annual revenue (last year) | $851.1M |
| Annual profit (last year) | $4.6M |
| Net profit margin | 0.54% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
